Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 4:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1009–1032 of 50,362 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Malignancies Clear all
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Improving Communication for Cancer Treatment: Addressing Concerns of Older Cancer Patients and Caregivers

NCT05436327
View directory record Official record
Conditions
Cancer, Aging, Communication
Interventions
Geriatric Assessment
Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
479 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 7, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Suspended Phase 1Phase 2 Interventional

A Study of VS-6766 and Cetuximab in Patients With Advanced Colorectal Cancer

NCT05200442
View directory record Official record
Conditions
Colorectal Cancer, Colorectal Adenocarcinoma, Colorectal Cancer Metastatic, Advanced Colorectal Carcinoma, Advanced Colorectal Adenocarcinoma
Interventions
VS-6766/avutometinib, Cetuximab, Pill Diary
Drug · Other
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Completed No phase listed Observational

Diagnostic Imaging Study for the Melanoma Advanced Imaging Dermatoscope (mAID)

NCT02470273
View directory record Official record
Conditions
Melanoma
Interventions
Not listed
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years to 80 Years
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
5
States / cities
Irvine, California • Orange, California • Sacramento, California + 2 more
Source: ClinicalTrials.gov public record
Updated May 24, 2023 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

Entinostat and Clofarabine in Treating Patients With Newly Diagnosed, Relapsed, or Refractory Poor-Risk Acute Lymphoblastic Leukemia or Bilineage/Biphenotypic Leukemia

NCT01132573
View directory record Official record
Conditions
Acute Leukemias of Ambiguous Lineage, Philadelphia Chromosome Negative Adult Precursor Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Lymphoblastic Leukemia
Interventions
entinostat, clofarabine, pharmacological study, laboratory biomarker analysis
Drug · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
21 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2010
U.S. locations
4
States / cities
Aurora, Colorado • Denver, Colorado • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 17, 2014 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Efficacy/Safety Study of ACTIQ® for Opioid-Tolerant Children and Adolescents With Breakthrough Pain (BTP)

NCT00236041
View directory record Official record
Conditions
Cancer, Breakthrough Pain
Interventions
ACTIQ®
Drug
Lead sponsor
Cephalon
Industry
Eligibility
3 Years to 15 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
30
States / cities
Little Rock, Arkansas • Los Angeles, California • Orange, California + 25 more
Source: ClinicalTrials.gov public record
Updated May 9, 2014 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

EXERCISING TOGETHER for Couples Coping With Cancer

NCT03630354
View directory record Official record
Conditions
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage III Breast Cancer AJCC v8, Breast Carcinoma, Colorectal Carcinoma, Malignant Solid Neoplasm, Prostate Carcinoma, Stage I Colorectal Cancer AJCC v8, Stage I Prostate Cancer AJCC v8, Stage II Colorectal Cancer AJCC v8, Stage II Prostate Cancer AJCC v8, Stage III Colorectal Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
Interventions
Exercise Intervention (supervised), Exercise Intervention (unsupervised), Informational Intervention, Questionnaire Administration
Behavioral · Other
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
35 Years to 80 Years
Enrollment
496 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 1, 2025 · Synced Oct 30, 2026, 4:46 PM EDT
Terminated Phase 2 Interventional Results available

Docetaxel, Carboplatin, and Rucaparib Camsylate in Treating Patients With Metastatic Castration Resistant Prostate Cancer With Homologous Recombination DNA Repair Deficiency

NCT03442556
View directory record Official record
Conditions
ATM Gene Mutation, BRCA1 Gene Mutation, BRCA2 Gene Mutation, Castration Levels of Testosterone, Castration-Resistant Prostate Carcinoma, Homologous Recombination Deficiency, Prostate Carcinoma Metastatic in the Bone, PSA Level Greater Than or Equal to Two, PSA Progression, Stage IV Prostate Adenocarcinoma AJCC v7
Interventions
Carboplatin, Docetaxel, Laboratory Biomarker Analysis, Rucaparib Camsylate, Rucaparib
Drug · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older · Male only
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 26, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Recruiting Not applicable Interventional

Magnetic Resonance (MR) Imaging to Determine High Risk Areas in Patients With Malignant Gliomas and to Design Potential Radiation Plans and to Examine Metabolite Changes in Gliomas and Other Solid Tumors

NCT00870129
View directory record Official record
Conditions
Brain Cancer, Glioma
Interventions
MRI and advanced MRI sequences
Procedure
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 14, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Suspended Phase 4 Interventional

Gadopiclenol in Contrast Enhanced MRI of the Prostate

NCT06226129
View directory record Official record
Conditions
Prostate Cancer
Interventions
Gadopiclenol
Drug
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older · Male only
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Not applicable Interventional

Improving Followup of Abnormal Colon Cancer Screening Tests

NCT00436137
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Patient mailing
Behavioral
Lead sponsor
Harvard Vanguard Medical Associates
Other
Eligibility
18 Years to 80 Years
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Newton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Nov 6, 2008 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Evaluate Rituximab in Obtaining PCR (Polymerase Chain Reaction) Negative Leukapheresis Product in Patients With Relapsed Follicular Lymphoma

NCT00856245
View directory record Official record
Conditions
Non-Hodgkins Lymphoma
Interventions
Rituximab
Drug
Lead sponsor
University of Kansas Medical Center
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
2
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 3 Interventional Results available

A Study of Capecitabine (Xeloda) and Bevacizumab as a First-line Therapy in Patients With Metastatic Colorectal Cancer

NCT00069095
View directory record Official record
Conditions
Colorectal Cancer
Interventions
Oxaliplatin 130 mg/m^2, Capecitabine 1000 mg/m^2, Bevacizumab 7.5 mg/kg, Placebo for bevacizumab 7.5 mg/kg, Oxaliplatin 85 mg/m^2, Leucovorin 200 mg/m^2, Fluorouracil 400 mg/m^2, Bevacizumab 5 mg/kg, Placebo for bevacizumab 5 mg/kg
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
2,035 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2009
U.S. locations
49
States / cities
Berkeley, California • Fountain Valley, California • Fullerton, California + 44 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2016 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

A Study of Low-Dose Decitabine in Relapsed or Refractory Acute Lymphocytic Leukemia (ALL)

NCT00349596
View directory record Official record
Conditions
Acute Lymphocytic Leukemia
Interventions
Decitabine
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 15, 2014 · Synced Oct 30, 2026, 4:46 PM EDT
Active, not recruiting Phase 2 Interventional

Improving Risk Assessment of AML With a Precision Genomic Strategy to Assess Mutation Clearance

NCT02756962
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Allogeneic stem cell transplant, Bone marrow aspiration, Punch skin biopsy, ClinSeq
Drug · Procedure · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 60 Years
Enrollment
107 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2029
U.S. locations
3
States / cities
Gainesville, Florida • St Louis, Missouri • Rochester, New York
Source: ClinicalTrials.gov public record
Updated Oct 29, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of XL309 (ISM3091) Alone and in Combination in Participants With Advanced Solid Tumors

NCT05932862
View directory record Official record
Conditions
Advanced Solid Tumor
Interventions
XL309, Olaparib
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
429 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
16
States / cities
Fountain Valley, California • Jacksonville, Florida • Orlando, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2025 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Brain Irradiation in Treating Patients With Limited-Stage Small Cell Lung Cancer

NCT00057746
View directory record Official record
Conditions
Lung Cancer
Interventions
Prophylactic cranial irradiation, 2.5 Gy fx, Prophylactic cranial irradiation, 2.0 Gy fx, Prophylactic cranial irradiation, 1.5 Gy fx
Radiation
Lead sponsor
Radiation Therapy Oncology Group
Network
Eligibility
Up to 120 Years
Enrollment
265 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
217
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 160 more
Source: ClinicalTrials.gov public record
Updated May 25, 2016 · Synced Oct 30, 2026, 4:46 PM EDT
Enrolling by invitation Not applicable Interventional

Effectiveness of a Cancer Exercise Program

NCT06039488
View directory record Official record
Conditions
Cancer
Interventions
Exercise
Behavioral
Lead sponsor
University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbia, South Carolina
Source: ClinicalTrials.gov public record
Updated Sep 15, 2023 · Synced Oct 30, 2026, 4:46 PM EDT
Completed No phase listed Observational Results available

Tenosynovial Giant Cell Tumors (TGCT) Observational Platform Project

NCT02948088
View directory record Official record
Conditions
Giant Cell Tumors
Interventions
Not listed
Lead sponsor
Daiichi Sankyo
Industry
Eligibility
18 Years and older
Enrollment
183 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Los Angeles, California • San Francisco, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 31, 2023 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

A Study of Atezolizumab (an Engineered Anti-Programmed Death-Ligand 1 [PDL1] Antibody) to Evaluate Safety, Tolerability and Pharmacokinetics in Participants With Locally Advanced or Metastatic Solid Tumors

NCT01375842
View directory record Official record
Conditions
Tumors, Hematologic Malignancies
Interventions
Atezolizumab
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
661 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2018
U.S. locations
16
States / cities
Scottsdale, Arizona • Los Angeles, California • Stanford, California + 10 more
Source: ClinicalTrials.gov public record
Updated Dec 11, 2018 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 1 Interventional

A Study of Enasidenib in People With Clonal Cytopenia of Undetermined Significance

NCT05102370
View directory record Official record
Conditions
Clonal Cytopenia of Undetermined Significance, CCUS Clonal Cytopenia of Undetermined Significance
Interventions
Enasidenib
Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
12
States / cities
Rochester, Minnesota • St Louis, Missouri • Basking Ridge, New Jersey + 9 more
Source: ClinicalTrials.gov public record
Updated Jan 27, 2026 · Synced Oct 30, 2026, 4:46 PM EDT
Withdrawn No phase listed Observational

Lapatinib Resistance in Patients With Breast Cancer

NCT00898573
View directory record Official record
Conditions
Breast Cancer
Interventions
lapatinib ditosylate, fluorescence in situ hybridization, gene expression analysis, mutation analysis, polymerase chain reaction, reverse transcriptase-polymerase chain reaction, cell sorting, immunohistochemistry staining method, laboratory biomarker analysis
Drug · Genetic · Other
Lead sponsor
Case Comprehensive Cancer Center
Other
Eligibility
Not listed
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
9
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 2, 2015 · Synced Oct 30, 2026, 4:46 PM EDT
Terminated Phase 2 Interventional Results available

A Study to Evaluate of the Efficacy and Safety of Imsidolimab (ANB019) in the Treatment of Acneiform Rash

NCT04697069
View directory record Official record
Conditions
Acneiform Eruptions
Interventions
Imsidolimab, Placebo
Biological
Lead sponsor
Vanda Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021
U.S. locations
5
States / cities
Tampa, Florida • Boston, Massachusetts • St Louis, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 22, 2025 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 2 Interventional Results available

Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The Lung

NCT00818441
View directory record Official record
Conditions
Carcinoma, Non-small Cell
Interventions
Dacomitinib (PF-00299804)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
31
States / cities
Orange, California • Pleasant Hill, California • Salinas, California + 15 more
Source: ClinicalTrials.gov public record
Updated Jan 8, 2019 · Synced Oct 30, 2026, 4:46 PM EDT
Completed Phase 2 Interventional

Docetaxel, Estramustine, and Thalidomide in Treating Patients With Androgen-Independent Metastatic Adenocarcinoma of the Prostate

NCT00083005
View directory record Official record
Conditions
Prostate Cancer
Interventions
docetaxel, estramustine phosphate sodium, thalidomide
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years and older · Male only
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
2
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 15, 2012 · Synced Oct 30, 2026, 4:46 PM EDT